(1S,9S)-tert-butyl 9-amino-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate | 88767-96-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,9S)-tert-butyl 9-amino-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate
• 英文别名: tert-Butyl (1S,9S)-9-amino-6,10-dioxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate；tert-butyl (4S,7S)-7-amino-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxylate
• CAS: 88767-96-8
• 化学式: C₁₄H₂₃N₃O₄
• 分子量: 297.354
• InChiKey: IXYCTLMKPJMGCC-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1S,9S)-tert-butyl 9-amino-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 3-({(1S,9S)-9-[(S)-2-Acetylamino-3-(4-phosphonooxy-phenyl)-propionylamino]-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carbonyl}-amino)-indan-1-carboxylic acid
  参考文献：
  名称：

  Structure-based design of peptidomimetic antagonists of p56lck SH2 Domain

  摘要：

  Starting from the tetrapeptide Ac-pYEEI-NHMe and using a structure-based approach, we have designed and synthesised a peptidomimetic ligand for p56(lck) SH2 domain containing a conformationally restricted replacement for the two glutamate residues. We have explored replacments for the isoleucine residue in the pY + 3 pocket and thus identified 1-(R)-amino-3-(S)-indane-acetic acid as the most potent replacement. We also report the X-ray crystal structures of two of the antagonists. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00167-1
• 作为产物：
  描述：

  (4S)-3-<(3S)-N,N'-bis(t-butoxycarbonyl)hexahydropyridazine-3-carboxy>-4-phenylmethyl-2-oxazolidinone 在 palladium on activated charcoal N-乙基吗啉 、 lithium hydroxide 、 sodium hydroxide 、 五氯化磷 、 硫酸 、 氢气 、 碳酸氢钠 、 肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 (1S,9S)-tert-butyl 9-amino-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate
  参考文献：
  名称：

  An efficient stereoselective synthesis of [3S(1S,9S)]-3-[[[9-(benzoylamino)octahydro-6,10-dioxo-6H-pyridazino-(1,2-a)(1,2)-diazepin-1-yl]-carbonyl]amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) inhibitor

  摘要：

  The title compound 1 is a potent interleukin-1 beta-converting enzyme (ICE) inhibitor. Recently, an efficient chiral synthesis of compound 1 has been accomplished in our labs. The overall yield of this 18-step stereoselective synthesis was 9.8%. (C) 1999 Elsevier Science Ltd. Ail rights reserved.

  DOI：

  10.1016/s0960-894x(99)00236-x

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Alam Muzaffar

  公开号：US20120230951A1

  公开（公告）日：2012-09-13

  The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本发明提供了用于治疗丙型肝炎病毒（HCV）感染的化合物、组合物和方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013053657A1

  公开（公告）日：2013-04-18

  The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection.

  本发明公开了式I和式II的化合物，其中式I和式II中的变量如本文所述。还公开了含有这种化合物的药物组合物，以及使用式I和式II的化合物治疗HCV感染的方法。
• INHIBITORS OF HCV NS5A
  申请人：Hoffman-La Roche Inc.

  公开号：US20150166514A1

  公开（公告）日：2015-06-18

  The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本发明提供了用于治疗丙型肝炎病毒（HCV）感染的化合物、组合物和方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• Method of preparing bicyclic intermediates from piperazic acid or an ester thereof useful in the manufacture of caspase inhibitors
  申请人：Vertex Pharmaceuticals, Incorporated

  公开号：US06703500B2

  公开（公告）日：2004-03-09

  The invention relates to a process for synthesizing piperazic acid and similar, ring-containing acids. The invention also relates to a process for simultaneously N(2)-acylating piperazic acid or an ester thereof and forming a bicyclic ring structure. The invention also relates to the use of either or both processes in a method of synthesizing a bicyclic compound useful as an intermediate for the production of an inhibitor of a caspase, particularly an inhibitor of interleukin-1&bgr; converting enzyme (“ICE”).

  本发明涉及一种合成哌嗪酸及类似含环酸的过程。该发明还涉及一种同时对哌嗪酸或其酯进行N(2)-酰化并形成双环环结构的过程。该发明还涉及以上任一或两种过程在合成一种双环化合物的方法中的应用，该双环化合物可作为生产一种caspase抑制剂的中间体，特别是一种白细胞介素-1β转化酶（“ICE”）抑制剂的中间体。
• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20050143436A1

  公开（公告）日：2005-06-30

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一类新型化合物，它们是白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以作为对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药物。本发明还涉及使用本发明的化合物和组合物抑制ICE活性、治疗介导IL-1、凋亡、IGIF和IFN-γ的疾病、减少IGIF和IFN-γ产生的方法。本发明还涉及制备N-酰氨化合物的方法。